ETV1 may also be critical for the survival and maintenance of the intrinsically imatinib-resistant, KIT-independent stem cell/progenitors in GIST, suggesting that this may be a therapeutic target to consider in KIT wild-type GIST [32]. This evidence concerns the gene ETV1 and gastrointestinal stromal tumor.